Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

Moderna said it is looking for growth overseas after the U.S. FDA refused to review its experimental flu shot and the country ...

Have you ever heard the old story about a person searching for lost keys under a streetlamp? When asked why there, the answer was simple: “That’s where the light is.” ...

Have you ever heard the old story about a person searching for lost keys under a streetlamp? When asked why there, the answer ...

At issue with Moderna's mRNA flu shot is communication from CBER to Moderna suggesting that the company’s vaccine be compared against a control shot designed more specifically for older people.

The measles situation in the United States is so bad that the disease is spreading south of the border. Answering a question ...

The House of Representatives passed a bill to block President Trump’s tariffs on Canada. Here are the names of the representatives who defied their parties.

Senior FDA official Vinay Prasad reportedly overrode his staff in deciding to reject Moderna's application for a new seasonal flu shot.

A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people ...

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...

It’s rare that FDA refuses to file an application, particularly for a new vaccine, which requires companies and FDA staff to ...